Optipharm.CO.LTD Total Liabilities

Latest as of June 2026: ₩15.42 Billion KRW ≈ $10.45 Million USD

Optipharm.CO.LTD total liabilities. Based on the latest financial reports, Optipharm.CO.LTD (153710) has total liabilities worth ₩15.42 Billion KRW (≈ $10.45 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Optipharm.CO.LTD (153710) asset resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Optipharm.CO.LTD (2015–2025)

Total liabilities of Optipharm.CO.LTD from 2015 to 2025. This chart illustrates how Optipharm.CO.LTD's total liabilities have evolved over time, based on quarterly financial data. Explore 153710 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Optipharm.CO.LTD Competitors by Total Liabilities

The table below lists competitors of Optipharm.CO.LTD ranked by their total liabilities.

Company	Country	Total Liabilities
JC Chemical Co. Ltd KQ:137950	Korea	₩265.18 Billion
Hofseth Biocare ASA OL:HBC	Norway	Nkr419.19 Million
Isbir Sentetik Dokuma Sanayi AS IS:ISSEN	Turkey	TL5.09 Billion
NVH Korea Inc KQ:067570	Korea	₩1.15 Trillion
Centara Hotels & Resorts Leasehold Property Fund BK:CTARAF	Thailand	฿900.00K
Regional Express Holdings Ltd AU:REX	Australia	AU$580.78 Million
Botnia Gold AB (publ) ST:BOTX	Sweden	Skr93.42 Million
Etherstack Plc AU:ESK	Australia	AU$12.36 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Optipharm.CO.LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Optipharm.CO.LTD's balance sheet.

Liquidity & Leverage Metrics

Optipharm.CO.LTD Total Liabilities Ratios Explained

Optipharm.CO.LTD total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	1.16	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.63	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.39	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Optipharm.CO.LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Optipharm.CO.LTD (2015–2025)

The table below shows the annual total liabilities of Optipharm.CO.LTD from 2015 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩15.37 Billion ≈ $10.42 Million	-3.84%
2024-12-31	₩15.98 Billion ≈ $10.83 Million	+13.11%
2023-12-31	₩14.13 Billion ≈ $9.58 Million	+16.10%
2022-12-31	₩12.17 Billion ≈ $8.25 Million	+19.17%
2021-12-31	₩10.21 Billion ≈ $6.92 Million	+35.43%
2020-12-31	₩7.54 Billion ≈ $5.11 Million	+23.42%
2019-12-31	₩6.11 Billion ≈ $4.14 Million	-15.07%
2018-12-31	₩7.20 Billion ≈ $4.88 Million	+1.97%
2017-12-31	₩7.06 Billion ≈ $4.78 Million	-0.27%
2016-12-31	₩7.08 Billion ≈ $4.79 Million	-46.06%
2015-12-31	₩13.12 Billion ≈ $8.89 Million	--

About Optipharm.CO.LTD

KQ:153710 Korea Diagnostics & Research

Market Cap

$45.68 Million

₩67.41 Billion KRW

Market Cap Rank

#22059 Global

#1372 in Korea

Share Price

₩4595.00

Change (1 day)

+9.80%

52-Week Range

₩4185.00 - ₩6200.00

All Time High

₩28900.00